ArticleCureus2021
Revealing Hepatitis B Virus as a Silent Killer: A Call-to-Action for Saudi Arabia.
Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Prevalence of Transfusion-Transmitted Viruses Among Blood Donors at King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia (2019-2024).New microbes and new infections · 2026Article
- Knowledge, Attitudes, and Preventive Practices Related to Hepatitis B Infection Among Adults in Saudi Arabia: A Nationwide Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Prevalence and Diagnostic Determinants of Hepatitis B Infection Among Saudi Adults: Implications for Targeted Screening and Early Detection.Diagnostics (Basel, Switzerland) · 2025Article
- Knowledge, Attitude and Practice Towards Hepatitis B Infection and HBV Vaccine Among the Healthy Population in Makkah, Saudi Arabia.Infection and drug resistance · 2025Article
- Article
- Seroprotection of Hepatitis B Vaccine in Dental Students Two Decades after Infant Immunization and the Possible Need for Revaccination.European journal of dentistry · 2023Article
- Epidemiology of Hepatitis B in Saudi Arabia from 2006 to 2021.Hepatic medicine : evidence and research · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Kingdom of Saudi Arabia (KSA) was the first country in the Middle East to adopt the hepatitis B virus (HBV) vaccine. Despite an expanded HBV immunization program and significant progress in HBV prevention in the country, HBV infection is a significant public health burden. This review lists coordinated solutions for healthcare stakeholders, patients, and health authorities to curb HBV and its impact in KSA. It further aims to draw policymakers' attention to key priorities to bridge HBV care gaps in the country.
methodsAs part of the pre-engagement activity, medical experts across KSA were interviewed to gain a preliminary understanding of the current unmet needs in HBV management in the country. Top-recommended action points derived from the pre-engagement activity were discussed. Key priority action points to curb the impact of HBV in KSA were identified.
resultsThe priority action points together with the challenges and unmet needs in the management and care of HBV in KSA were: (a) establish a national-level registry, (b) implement screening campaigns, (c) improve linkage of care between primary care physicians (PCPs) and specialists, and (d) increase PCP education and awareness.
conclusionThis work is an endeavor to set the stage for a strategic policy framework aimed at eliminating HBV in KSA. The action points/steps for the identified priorities must run parallelly across various regions in KSA, to successfully manage and further eliminate the threat of HBV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.